A subscription to JoVE is required to view this content. Sign in or start your free trial.
A method was developed to visualize dye extravasation due to blood-brain barrier (BBB) breakdown by administering two fluorescent dyes to mice at different time points. The use of glycerol as a cryoprotectant facilitated immunohistochemistry on the same sample.
Fluorescent dyes are used to determine the extent of dye extravasation that occurs due to blood-brain barrier (BBB) breakdown. Labeling with these dyes is a complex process influenced by several factors, such as the concentration of dyes in the blood, permeability of brain vessels, duration of dye extravasation, and reduction in dye concentration in the tissue due to degradation and diffusion. In a mild traumatic brain injury model, exposure to blast-induced shock waves (BSWs) triggers BBB breakdown within a limited time window. To determine the precise sequence of BBB breakdown, Evans blue, and fluorescein isothiocyanate-dextran were injected intravascularly and intracardially into mice at various time points relative to BSW exposure. The distribution of dye fluorescence in brain slices was then recorded. Differences in the distribution and intensity between the two dyes revealed the spatiotemporal sequence of BBB breakdown. Immunostaining of the brain slices showed that astrocytic and microglial responses correlated with the sites of BBB breakdown. This protocol has broad potential for application in studies involving different BBB breakdown models.
Blood-brain barrier (BBB) breakdown and dysfunction are caused by systemic inflammation, infections, autoimmune diseases, injuries, and neurodegenerative diseases1. In mild traumatic brain injury (mTBI) resulting from exposure to blast-induced shock waves (BSWs), a significant correlation has been observed between the intensity of BSWs and the amount of fluorescent dye leakage due to BBB breakdown2,3,4. One notable feature of BBB breakdown in mTBI is that it begins immediately or within a few hours after exposure to BSWs and is usually a transient process that lasts for about a week before delayed, chronic neurological disorders emerge3,5,6,7. Although the details remain unclear, BBB breakdown is part of the long-lasting pathological cascade and may also serve as a prognostic factor in mTBI6. Therefore, understanding the spatial and temporal distributions of BBB breakdown in the brain is important.
Fluorescent dyes are used to determine the extent of BBB breakdown3,8. Because the blood concentration of the dyes and the magnitude and extent of BBB breakdown change over time, caution is required when interpreting images of dye extravasation. For instance, the absence of dye extravasation does not necessarily indicate the absence of BBB breakdown. No BBB breakdown may be detected before or after an increase in the dye's blood concentration. Even if the dye successfully accumulated where BBB breakdown occurred, it may have been lost over time after the breakdown ceased. In general, water-soluble and biologically inert substances are quickly excreted in the urine9. Therefore, to determine whether BBB breakdown occurs at a specific time, the most reliable results are obtained when a fluorescent dye is administered into the bloodstream for a short period immediately before fixing the animal. Commercially available fluorescein isothiocyanate (FITC)-dextran with a specific molecular weight should be used in this manner.
Evans blue is a widely recognized blue azo dye with a strong affinity for serum albumin. The dye exhibits red fluorescence when excited by green light in biological systems2. Due to its inert nature, the Evans blue-serum albumin complex remains in the blood for up to 2 h, making it a useful 69 kDa tracer for labeling regions with a compromised BBB for at least this duration10,11. Therefore, it is important to consider potential uncertainties surrounding the pharmacokinetics and toxicity of Evans blue9. However, a recent study showed that Evans blue continues to accumulate in areas where the BBB is absent or disrupted7. This feature enabled Evans Blue to record the history of the BBB breakdown, while FITC-dextran was used to record the BBB breakdown at a specific time point after the BSW exposure. Although Evans blue can be administered intravenously or intraperitoneally10, intravenous administration is preferred for time-sensitive experiments. This study aimed to demonstrate the use of Evans blue and FITC-dextran to detect the spatiotemporal distribution of BBB breakdown following exposure to BSW.
Second, the study presented a technique for freezing brain slices after observing the fluorescence of BBB breakdown and preparing thinner slices suitable for immunohistochemical procedures. The use of glycerol as a mounting medium and cryoprotectant simplifies the immunohistochemistry process. By comparing images of BBB breakdown with those from immunohistochemistry, the spatiotemporal distribution of BBB breakdown can be correlated with the tissue response of the same sample.
All experiments were conducted in accordance with the ethical guidelines for animal experiments established by the National Defense Medical College (Tokorozawa, Japan). The study protocol was approved by the Committee for Animal Research at the National Defense Medical College (approval no. 23011-1). Male C57BL/6J mice aged 8 weeks and weighing 19-23 g were used in this study. Details of the reagents and equipment used are listed in the Table of Materials.
1. Animal preparation
NOTE: This is a modified protocol that increases the amount of medetomidine by 2.5 times compared with the original one12. The dosages for medetomidine hydrochloride, midazolam, and butorphanol were 0.75 mg/kg, 4 mg/kg, and 5 mg/kg, respectively.
2. BSW exposure
NOTE: An in-house shock tube was used in this study14.
3. Evans blue injection into the tail vein
NOTE: Evans blue solution should be administered intravenously without anesthesia. In the presence of anesthesia, the dye often does not penetrate the body sufficiently, likely due to decreased blood pressure and body temperature13. Evans blue was administered at a dose of 100 mg/kg.
4. Transcardial perfusion with FITC-dextran solution and fixation
5. Brain tissue processing
NOTE: Even if perfusion fixation is complete, Evans blue and FITC-dextran may disperse into the buffer. Therefore, the procedures leading up to step 6.8 should be completed within a week after perfusion fixation. Additionally, avoid exposing the sample to light.
6. Fluorescence measurement of dye extravasation
NOTE: Fluorescence labeling efficiency varies from mouse to mouse. Therefore, fluorescence intensity needs to be normalized. Fluorescence values are expressed relative to those within the gigantocellular reticular nucleus (GRN) because this region is minimally affected by BSW treatment.
7. Cryosectioning and immunohistochemistry
Figure 1A shows the time course of dye injection in relation to the onset of BSW, with a peak overpressure of 25 kPa. In the 'Post' protocol, Evans blue solution was administered intravascularly 2 h before FITC-dextran perfusion, which was conducted 6 h, 1 day, 3 days, and 7 days after BSW exposure. In the 'Pre' protocol, Evans blue solution was injected immediately before BSW exposure. In the 'Post' protocol, the concentration of Evans blue is expected to reach its m...
A novel double-labeling technique using Evans blue and FITC-dextran was used to accurately visualize the precise spatiotemporal distribution of BBB breakdown in a single brain. In the low-intensity BSW model, noticeable variations in the extent, location, and degree of dye extravasation were observed in examined brains (Figure 2 and Figure 3). Between-dye mismatches revealed that BBB breakdown commenced approximately 3 h after BSW exposure, with substantial remo...
The authors have nothing to disclose.
We thank Mayumi Watanabe for the cryosectioning technique. This work was supported by an Advanced Research on Military Medicine grant from the Ministry of Defense, Japan.
Name | Company | Catalog Number | Comments |
10% Formalin Neutral Buffer Solution | FUJIFILM Wako Chemicals | 062-01661 | |
Anti GFAP, Rabbit | DAKO-Agilent | IR524 | |
Anti Iba1, Rabbit | FUJIFILM Wako Chemicals | 019-19741 | |
Chicken anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 | Thermo Fisher Scientific | A-21200 | |
Cryo Mount | Muto Pure Chemicals | 33351 | tissue freezing medium |
Domitor | Orion Corporation | medetomidine | |
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 | Thermo Fisher Scientific | A10040 | |
Evans Blue | Sigma-AldrichΒ | E2129 | |
Falcon 24-well Polystyrene Clear Flat Bottom Not Treated Cell Culture Plate, with Lid, Individually Wrapped, Sterile, 50/Case | CORNING | 351147 | |
Fluorescein isothiocyanateβdextran average mol wt 40,000 | Sigma-AldrichΒ | FD40S | FITC-dextran |
Glass Base Dish 27mm (No.1 Glass) | AGC TECHNO GLASS | 3910-035 | 35 mm glass bottom dish |
IX83 Inverted Microscope | OLYMPUS | ||
MAS Hydrophilic Adhesion Microscope Slides | Matsunami Glass | MAS-04 | |
MatsunamiΒ Cover Glass (No.1)Β 18 x 18mm | Matsunami Glass | C018181 | |
Midazolam Injection 10mg [SANDOZ] | Sandoz | ||
Paraformaldehyde EMPROVE ESSENTIAL DAC | Merck Millipore | 1.04005.1000 | |
Peristaltic Pump | ATTO | SJ-1211 II-H | |
RODENT BRAIN MATRIX Adult Mouse, 30 g, Coronal | ASI INSTRUMENTS | RBM-2000C | brain slicer |
Vetorphale | Meiji Animal Health | VETLI5 | butorphanol |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright Β© 2025 MyJoVE Corporation. All rights reserved